KRAS mutations contribute to cell proliferation and survival in numerous cancers, including colorectal cancers (CRC). One pathway through which mutant KRAS acts is an inflammatory pathway that involves the kinase IKK and activates the transcription factor NF-kB. BRAF, a kinase that is downstream of KRAS, is mutated in a subset of CRC and is predictive of poor prognosis and therapeutic resistance. We found that, in contrast to mutant KRAS, mutant BRAF (BRAF V600E ) did not trigger NF-kB activation but instead triggered the phosphorylation of a proteolytic fragment of IKKa (p45-IKKa) in CRC cells. BRAF V600E CRC cells had a high abundance of phosphorylated p45-IKKa, which was decreased by a RAF inhibitor. However, the abundance and DNA binding of NF-kB in these cells were unaffected by the RAF inhibitor, and expression of BRAF V600E in human embryonic kidney-293T cells did not activate an NF-kB reporter. Moreover, BRAF-induced transformation of NIH-3T3 cells and BRAFdependent transcription required phosphorylation of p45-IKKa. The kinase TAK1, which was associated with the endosomal compartment, phosphorylated p45-IKKa. Inhibition of endosomal vacuolar adenosine triphosphatase (V-ATPase) with chloroquine or bafilomycin A1 blocked p45-IKKa phosphorylation and induced apoptosis in BRAF-mutant CRC cells independent of autophagy. Treating mice with V-ATPase inhibitors reduced the growth and metastasis of BRAF V600E xenograft tumors in the cecum of mice.
INTRODUCTION
Colorectal cancer (CRC) is the second leading cause of death from cancer in Western populations. Progression from adenoma to invasive CRC requires a number of genetic alterations, including those encoding adenomatous polyposis coli, the transcription factor SMAD4, or the guanosine triphosphatase KRAS. Activating mutations of KRAS are present in about 40% of advanced CRC. Clinically relevant RAS mutations are difficult to target and preclude the use of epidermal growth factor receptor (EGFR) inhibitors, such as cetuximab or panitumumab, in advanced metastatic CRC (1) (2) (3) . RAS signaling through the RAF kinase family induces the subsequent activation of the mitogen-activated protein/extracellular signal-regulated kinase 1 and 2 (MEK1/2), extracellular signal-regulated kinase 1 and 2 (ERK1/2), and a variety of targets, including key growth factors. The importance of the RAS-RAF pathway and the identification of BRAF mutations in various types of cancer, including in 5 to 15% of all CRC cases, pointed out the possibility of using RAF inhibitors for therapeutic purposes. BRAF inhibitors have been approved to treat metastatic melanoma patients (4, 5) . Unfortunately, therapeutic efficacy in CRC patients is disappointing, perhaps because some RAF inhibitors that block the proliferation of BRAF-mutant cells are ineffective against RAS-mutant cells and may even activate the mitogen-activated protein kinase (MAPK) pathway in the presence of wild-type RAF (6) (7) (8) (9) . The efficacy of BRAF inhibitors in CRC can also be suppressed by hepatocyte growth factor, which is secreted into the tumor microenvironment (10) upon overexpression of CRAF (11) or EGFR (12) ; thus, many tumors that initially respond to RAF inhibition tend to develop drug resistance. Better outcomes are obtained with combinations of BRAF and MEK inhibitors, especially in melanoma patients (13) , or with different MEK inhibitors that preferentially target KRAS-or BRAF-mutant tumors (10, 14) . Yet, the identification of new druggable targets downstream of RAS may provide new therapeutic strategies.
The nuclear factor kB (NF-kB) pathway is a key regulator not only of innate and acquired immunity but also of cancer progression. Activation of NF-kB occurs downstream of the inhibitor of NF-kB (IkB) kinase (IKK) complex, composed of two catalytic subunits, IKKa and IKKb, and the regulatory subunit IKKg/NF-kB essential modulator (NEMO). Phosphorylationmediated degradation of IkB is induced by IKKb downstream of transforming growth factor-b-activated kinase 1 (TAK1), leading to the nuclear translocation of the NF-kB factor (mostly the p65/p50 complex) and canonical NF-kB activation. Activation and recruitment of TAK1 to the IKK complex is induced by K63-linked polyubiquitination of tumor necrosis factor-a (TNFa) receptor-associated factor (TRAF) and NEMO, which acts as a bait for the TAK1 adaptors TAB2 and TAB3 [reviewed in (15) ]. An alternative NF-kB pathway is mediated independently of IKKb, NEMO, and TAK1 but requires the activation of IKKa by the kinase NF-kB-inducing kinase (NIK) upon NIK protein stabilization. Active IKKa (and NIK) phosphorylates p100, thereby inducing its proteolytic processing into p52, which translocates to the nucleus together with RelB to activate transcription (16) . Additional substrates for IKKa are histone H3 (17, 18) , Aurora A kinase (19) , or the nuclear corepressors SMRT (silencing mediator for retinoid and thyroid receptors) (20) and NCoR (nuclear receptor corepressor) (21) . In squamous cell carcinoma, IKKa induces HOX and IRX transcription through the chromatin release of SUMOylated IkBa (22) , and in CRC, IKKa facilitates transcription of the Notch targets HES1 and HEY1 and the antiapoptotic gene cIAP2 associated with nuclear corepressor inactivation (21, 23) . In contrast, nuclear active IKKa represses the metastasis-related gene Maspin in prostate cancer cells (24) .
Oncogenic KRAS induces canonical NF-kB, thus inhibiting apoptosis in different cancer systems (25) (26) (27) (28) (29) . In lung cancer, KRAS, through PKC (protein kinase C) and p62, induces TRAF6 and NEMO polyubiquitination leading to TAK1-dependent phosphorylation of IKKb (27, 30) , whereas in pancreatic cancer, a paracrine loop involving interleukin-1a is responsible for activating NF-kB (25) . Inhibition of TAK1 (26) or other NF-kB elements (31, 32) reverts cancer progression in the presence of KRAS mutations. However, little is known about the putative contribution of NF-kB or particular NF-kB constituents to BRAFdriven tumorigenesis. Notably, general NF-kB inhibitors are extremely toxic, and they can either suppress or promote cancer in a context-dependent manner, which stands against their possible use in human therapies (33) . Recently, we identified a proteolytic fragment of IKKa, which we called p45-IKKa, that is generated in the early endosomes (EE) of CRC cells by the proteolytic activity of cathepsins and whose in vitro processing is favored at acidic pH. Phosphorylated p45-IKKa associates with NEMO and full-length IKKa to phosphorylate the nuclear corepressor SMRT and histone H3, thus promoting specific gene transcription. Supporting the functional relevance of phosphorylated p45-IKKa, an IKKa mutant that is not processed to the p45 form (IKKa3M) fails to drive specific transcription leading to increased apoptosis of CRC cells (34) . Here, we study the mechanisms that regulate p45-IKKa activation in CRC cells with different mutations for KRAS or BRAF and test the possibility of using this information to design specific therapies for a subset of cancer patients.
RESULTS
BRAF is associated to p45-IKKa activity in CRC cells but has no impact on NF-kB We previously demonstrated that nuclear phosphorylated IKK is associated with advanced disease in human CRC (34) . By analyzing 184 adenoma and carcinoma samples and the corresponding paired distal normal mucosa from 98 patients, we now found that 70% of samples with high abundance of nuclear phosphorylated IKK were also positive for phosphorylated ERK1/2 staining, compared with 20% of phosphorylated ERK1/2 positivity in samples with negative or low nuclear abundance of phosphorylated IKK (Fig. 1, A and B) , suggestive of a link between IKK activation and the MAPK pathway. In a set of 93 samples that were examined for KRAS, BRAF, and PI3K (phosphatidylinositol 3-kinase) mutations, we observed that BRAF mutations were significantly associated with higher nuclear abundance of phosphorylated IKK (Fig. 1, C and D) , further connecting signaling through the BRAF-MAPK pathway with IKK activation in CRC cells. Mutant BRAF is commonly associated with the serrated pathway in CRC. Thus, we subclassified our set of samples to determine whether nuclear IKK activity was restricted to any specific lesion subtype. The group of samples with high amounts of nuclear phosphorylated IKK contained not only all serrated lesions (including all BRAF-mutated polyps) but also several conventional polyps and carcinomas, including those containing the BRAF V600E mutation (Fig. 1E) . Next, we determined the abundance of active IKK in CRC cell lines carrying mutations in KRAS at codon 13 (HCT116 and DLD1) or codon 12 (SW480 and LS174T) or in BRAF (WiDr and HT29), or in cells carrying no mutations in these genes (LIM1215). We found that cells with mutant BRAF contained the highest amounts of activated IKK (mostly corresponding to the previously described p45-IKKa), although activated p45-IKKa was also detectable in KRAS-mutant cells ( fig. S1, A and B) . To directly test whether BRAF regulates the phosphorylation of p45-IKK, we treated CRC cells carrying the BRAF V600E mutation with the RAF inhibitor AZ628. AZ268 abrogated the detection of phosphorylated p45-IKKa in these cells, compared with the partial effects of MEK1/2 or PI3K inhibition (Fig. 1F) . Inhibition of BRAF also reduced p45-IKKa phosphorylation in KRAS-mutated cells after 2 hours of treatment (fig. S1B). Notably, neither the phosphorylation of full-length IKKa/b (85 and 87 kD, respectively) nor the abundance of IkBa and p100/p52 was affected by AZ628, indicating that oncogenic BRAF does not modulate NF-kB activity in CRC cells. Consistent with this interpretation, we did not detect significant NF-kB DNA binding activity in the nuclear extracts of HT29 and WiDr cells (BRAF-mutated) by EMSA, whereas NF-kB activity in cells with KRAS codon 12 mutations was found at a comparable abundance to that in TNFa-treated wild-type cells (Fig. 1G) . Moreover, BRAF V600E failed to activate the 3xkB-luciferase reporter construct when transduced into human embryonic kidney (HEK) 293T cells ( fig. S1C ).
Next, we tested whether BRAF inhibition affected p45-IKK activity by analyzing the amounts of phosphorylated Ser 10 of histone H3 and SMRT (both isoforms of 150 and 300 kD). We found reduced abundance of both phosphorylated substrates in the presence of the BRAF inhibitor, which were partially recovered after washout and linked to p45-IKK reactivation (Fig. 1H) . Time-course experiments using BRAF-mutant cells demonstrated that p45-IKK phosphorylation started 5 min after washing out the BRAF inhibitor (reaching maximum recovery at 1 hour) (fig. S1D), thus suggesting that IKK activation downstream of BRAF is cellautonomous. Consequently, HT29 or WiDr conditioned media only induced a marginal activation of p45-IKK and ERK1/2 in LIM1215 cells (wild type for KRAS and BRAF) that was abrogated when the RAF inhibitor was added (fig. S1E).
To further investigate the contribution of IKK to BRAF signaling in CRC, we performed microarray expression analysis of HT29 and WiDr cells treated for 16 hours with the RAF inhibitor. About 5000 genes were significantly repressed in both cell lines in three independent replicates, which clustered into the functional categories of cell cycle, DNA repair, and MAPK signaling, among others, as determined by Ingenuity Pathway Analysis. This analysis failed to identify the canonical or alternative NF-kB pathways (Fig. 1I ), in agreement with our Western blot analysis (Fig. 1F) . We previously demonstrated that p45-IKK was derived from full-length IKKa (34) . Hence, we knocked down IKKa in BRAF-mutant cells using specific shRNA (fig. S1F) and examined its effect on gene transcription in comparison with the effects of BRAF inhibition. We identified 4450 genes whose expression was significantly reduced 72 hours after shRNA transduction, including 35% of the genes inhibited by AZ628 treatment (Fig. 1J) . Genes identified as common targets of BRAF and IKKa (1768 genes) fall into the functional categories of cellular apoptosis, cell migration, and cell proliferation, among others; again, the NF-kB pathway was not detected in the analysis ( Fig. 1K and fig. S1G ). In agreement with these results, CRC cells carrying the V600E mutation in BRAF (BRAF   V600E   ) were resistant to treatment with BAY65-5811 ( Fig. 1L ), which specifically inhibits canonical NF-kB but not the alternative IKKa and p45-IKK pathways (fig. S1, H and I). In contrast, BAY65-5811 significantly reduced the proliferation of KRAS-mutant CRC cells (Fig. 1L ), indicating that oncogenic KRAS, but not BRAF, signals through canonical NF-kB. Together, these results indicate that BRAF mutation induces p45-IKK activation but not NF-kB activity.
p45-IKKa activity is induced by BRAF and is required for BRAF-mediated transformation
We next tested whether mutant BRAF was sufficient to induce p45-IKKa phosphorylation. Ectopic expression of the constitutively active BRAF V600E promoted p45-IKK phosphorylation in NIH-3T3, with a minor effect on the abundance of full-length phosphorylated IKKa/b, p100/p52, and IkBa. Similar to that found in the CRC cell lines, pharmacologic inhibition of BRAF activity, but not of MEK1/2, prevented phosphorylation of p45-IKKa induced by BRAF V600E ( Fig. 2A) . Consistent with the fact that BRAF acts downstream of KRAS, oncogenic KRAS G12V increased the abundance of phosphorylated p45-IKKa in NIH-3T3 cells ( Next, we investigated the contribution of p45-IKKa to BRAF V600E -induced cell transformation. BRAF V600E failed to induce transformation foci in IKKa-deficient mouse embryonic fibroblasts (MEFs) compared to wild-type MEFs (Fig. 2D ). Ectopic expression of wild-type IKKa restored the transformation capacity of BRAF V600E in mutant MEFs, in contrast to the uncleavable IKKa3M construct (Fig. 2E ) that is defective for p45-IKKa generation ( fig. S2B ). An intermediate phenotype was obtained using a point mutant (S400W) with reduced p45-IKKa processing capacity (34) . Knockdown of IKKa in NIH-3T3 cells reduced their transformation capacity by BRAF but not by KRAS ( fig. S2C) , further supporting the notion that IKKa is specifically required for BRAF-mediated transformation.
Activation of p45-IKKa by BRAF is mediated by TAK1
TAK1 and NIK are the major kinases that activate the IKK complex. We found that ectopic expression of BRAF V600E did not affect NIK abundance, and NIK overexpression did not induce p45-IKKa phosphorylation in HEK 293T cells ( fig. S3A ). Therefore, we tested whether activation of p45-IKKa downstream of BRAF was dependent on TAK1. Our results indicated that knocking down TAK1 with one of two shRNAs reduced phosphorylated p45-IKK amounts in HT29 and WiDr cells to values comparable with that of wild-type LIM1215 cells (Fig. 3, A and C) . Similarly, pharmacologic inhibition of TAK1 activity with 5Z-7-oxozeaenol (16 hours of treatment) abrogated p45-IKKa phosphorylation in BRAF-mutated cells, associated with a slight reduction of total p45-IKKa abundance (Fig. 3, B and C). However, 5 to 30 min of treatment with 5Z-7-oxozeaenol significantly reduced p45-IKK phosphorylation without affecting total p45-IKKa abundance (Fig. 3D ). Then, we tested whether TAK1 activity was required for p45-IKK phosphorylation after BRAF inhibition and reactivation in WiDr and HT29 cells. As we previously found, phosphorylation of p45-IKK was detected 5 min after washing out the RAF inhibitor, but it was precluded in the presence of the TAK1 inhibitor (Fig. 3E) . Consistent with the requirement for TAK1 in p45-IKK activation and function, TAK1 knockdown prevented the transformation of NIH-3T3 cells induced by oncogenic BRAF V600E (Fig. 3F ) and induced apoptosis in HT29 and WiDr cells ( fig. S3B) .
In HT29 cells, TAK1 kinase physically associated with p45-IKKa as determined by coprecipitation of endogenous proteins. Notably, this interaction was reduced after RAF or TAK1 inhibition but was restored after Blots are representative of three experiments. All data are means ± SD from three independent experiments. *P < 0.05, **P < 0.01, ***P < 0.001, unpaired two-tailed t test.
washing out the inhibitors (Fig. 3G ). As expected, we did not detect any TAK1 or IKKa in the immunoglobulin G (IgG) control precipitates ( fig.  S3C) . We also performed a reciprocal experiment using a monoclonal antibody (881H3) that preferentially precipitates the p45-IKKa complex in its native form (34) . We detected small amounts of phosphorylated TAK1 in p45-IKKa precipitates in both untreated and BRAF-inhibited cells (Fig.  3H) , which significantly increased after washing out the BRAF inhibitor.
Together these results indicate that TAK1 displays a dynamic interaction with p45-IKKa that is modulated by BRAF, leading to p45-IKKa activation and function.
Inhibition of endosome acidification induces apoptosis of BRAF-mutant cells in a p45-IKKa-dependent manner
We previously demonstrated that p45-IKKa activation was linked to the endosomal compartment of CRC cells (34) . Using sucrose density gradients followed by Western blot analysis from HT29 cells, we found that IKKa (both p85 and p45) and phosphorylated p45-IKKa eluted in the fractions corresponding to the EE together with nonphosphorylated fulllength IKKa, NEMO, and active TAK1 (Fig. 4A ). Using a previously described endosome protection assay (35) that allows the recovery of endosome-associated proteins, we confirmed the presence of several IKKa species [the identity of which was confirmed using IKKa-deficient MEFs ( fig. S4A)] , NEMO, TAK1, and BRAF in the endosomal compartment of different CRC cell lines ( fig. S4B ). Therefore, we asked whether inhibitors of endosomal acidification affect p45-IKKa processing or activation, as well as the subcellular distribution of p45-IKKa and its regulatory elements in BRAF-or KRAS-mutant cells. Inhibition of the endosomal function by chloroquine or bafilomycin A1 reduced the total amount of phosphorylated p45-IKKa in BRAF V600E CRC cells (Fig. 4B ) and BRAF
V600E
-transduced NIH-3T3 cells ( fig. S4C ), associated with a decrease in the total and endosomal abundance of phosphorylated TAK1 (Fig. 4C and fig. S4D ). However, we detected some accumulation of NEMO and TAK1 in the endosomal extracts after bafilomycin A1 treatment (Fig. 4C) .
On the other hand, inhibition of endosomal acidification did not result in a consistent reduction in the abundance of phosphorylated ERK1/2, further suggesting that the activation of p45-IKKa and ERK1/2 is mediated by divergent pathways downstream of BRAF. In contrast with their effect on p45-IKKa and TAK1 activity, both chloroquine and bafilomycin A1 increased IkBa phosphorylation ( fig. S4D) , which was an indication of canonical NF-kB signaling. Detection of the endosomal/ lysosomal component cathepsin B and/or the early endosomal marker Immunohistochemical analysis of control and treated tumors using the specific antibody to active P-IKK. Scale bars, 50 mm. Data are means ± SD of tumors obtained from five animals in each experimental group. *P < 0.05, **P < 0.01, ***P < 0.001, unpaired twotailed t test.
Rab5 and the absence of the cytoskeletal component tubulin, the nuclear protein Sin3A, and the mitochondrial marker TOM20 confirmed the purity of the endosomal fractions in the different assays.
Chloroquine and bafilomycin A1 are used for different clinical applications and proposed as anticancer agents on the basis of their anti-autophagic activity. However, we speculated that these compounds might distinctively affect CRC cells carrying BRAF mutations because of their effect on p45-IKKa activation. We found that bafilomycin A1 treatment decreased the proliferation of BRAF-mutant CRC cells (HT29 and WiDr) at concentrations that were substantially lower than those affecting KRAS-mutant (HCT116, LS174T, DLD1, and SW480) or BRAF/KRAS-wild-type cells (LIM1215 and CaCo2): IC 50 (median inhibitory concentration) ≈ 0.5 nM for BRAF-mutant cells compared with an IC 50 > 2 nM for most of the KRAS-mutant cells, with the exception of SW480 cells (IC 50 = 1.5) (Fig.  4, D and E) . Comparable effects on cell proliferation and decreased p45-IKKa abundance were observed after knocking down endosomal vacuolar adenosine triphosphatase (V-ATPase) using specific shRNA in BRAFmutant CRC cells ( fig. S4E ). In contrast, we did not observe any association between the presence of mutant BRAF and the sensitivity of CRC cells toward the autophagy inhibitors 3-MA (Fig. 4F) and MY1485 (fig.  S4F ). In agreement with the concept that p45-IKKa mediates the inhibitory effects of bafilomycin A1 on BRAF-mediated transformation, ectopic expression of constitutively active p45-IKKa EE reduced the sensitivity of HT29 and WiDr cells to chloroquine (Fig. 4G and fig. S4G ) and recovered the transformation capacity of BRAF V600E in chloroquine-treated NIH-3T3 cells (Fig. 4, H and I) . In addition, all tested target genes common to BRAF and IKK were significantly repressed after cells were treated with bafilomycin A1 for 36 hours (Fig. 4J) .
The proliferative inhibition imposed by endosomal inhibitors in BRAFmutant cells was likely due to increased apoptosis as determined by increased poly(adenosine diphosphate-ribose) polymerase cleavage and active caspase-3 detection (Fig. 4K) , whereas no significant changes in the cell cycle profile were detected. Accumulation of the autophagy marker LC3B-II after bafilomycin A1 treatment was comparable with the resistant LIM1215 cells and the BRAF-mutant HT29 and WiDr cells, further indicating that enhanced bafilomycin A1 sensitivity was independent of autophagy inhibition (Fig. 4K) . Conversely, treatment with the autophagy inhibitors 3-MA and MY1485 did not affect the abundance of phosphorylated p45-IKKa ( fig. S4H ). Inhibition of cell proliferation in BRAF-mutant cells by chloroquine or bafilomycin A1 was slightly increased with the combined treatment ( fig. S4I ) but was not improved by the addition of the canonical NF-kB inhibitor BAY65-5811 ( fig. S4J) . We also tested whether extracellular acidosis, which occurs in the central areas of solid tumors and contributes to tumor progression, affects p45-IKKa abundance or activity in cultured CRC cell lines. By Western blotting analysis, we found that extracellular acidification (at pH 5.0 for 24 hours) did not further increase the abundance of total or phosphorylated p45-IKKa in BRAF-mutant CRC cells compared with the controls (fig. S4K ), whereas some increase was observed in KRAS-mutant SW480 cells.These data indicate that p45-IKKa activation downstream of BRAF takes place in the endosomal compartment and can be blocked by V-ATPase inhibitors, which makes BRAF-mutant cells particularly sensitive to these inhibitors.
Endosomal acidification inhibitors reduce the growth and metastatic capacity of BRAF-mutated CRC cells
We have shown that endosomal acidification inhibitors induce apoptosis of CRC cells carrying a high amount of active p45-IKKa, being the most sensitive among those carrying BRAF mutations. To test whether this selectivity was maintained in vivo, we performed tumor xenograft experiments. We first generated subcutaneous tumors from DLD1 and HCT116 (KRAS mutant) or WiDr and HT29 (BRAF mutant) cells. Comparable fragments of the tumors were orthotopically implanted in the wall of the cecum of immune-compromised animals. When tumors were detectable by palpation, animals carrying homogeneous tumors were randomly segregated into three groups for treatment: control, bafilomycin A1 alone, or bafilomycin A1 combined with the topoisomerase inhibitor irinotecan. After 3 weeks, the animals were euthanized and the tumors were analyzed. We found that bafilomycin A1-treated mice bore tumors that were significantly smaller than those of control animals, and that WiDr-and HT29-derived tumors were more sensitive to bafilomycin A1 than were DLD1-and HCT116-derived tumors. Moreover, this effect was significantly enhanced by combined treatment with the topoisomerase inhibitor irinotecan (Fig. 5, A to C) . The toxicity of bafilomycin A1 was also greater than that of irinotecan treatment alone, as determined in an independent set of experiments ( fig. S5A ). Bafilomycin A1 barred the capacity of BRAF-mutant-derived orthotopic xenografts to generate intraperitoneal implants in the animals, both in the single treatment and in the irinotecan combination groups (Fig. 5D) . Moreover, the few intraperitoneal tumors detected in bafilomycin A1-treated animals were also reduced in size compared with the controls (Fig. 5D) , further indicating Our data suggest a mechanism by which mutant BRAF specifically induces activation of p45-IKKa associated with the endosomal compartment of tumor cells, most likely through TAK1. Inhibition of endosomal V-ATPase activity (and hence endosomal acidification) by bafilomycin A1 or chloroquine prevents p45-IKKa activation, leading to increased cell death. In contrast, KRAS-mutant cells are resistant to endosomal acidification inhibition, likely due to their capacity to induce NF-kB.
that bafilomycin A1 treatment affected p45-IKKa activity in vivo. Immunohistochemical analysis of the excised tumors at the end of the experiment showed detectable amounts of phosphorylated IKK in control tumor samples, which were significantly reduced in the remaining tumor mass from animals treated with bafilomycin A1 or with the combined treatment (Fig. 5E) . Nevertheless, by qRT-PCR, we did not detect a significant reduction in the expression of the IKKa targets BCL2L1, BIRC5, CD44, and CHEK1 in bafilomycin A1-treated tumors ( fig.  S5B ). These results support previous publications that suggest the potential of using endosome inhibitors in anticancer cocktails (36) (37) (38) (39) and provide a mechanism-driven treatment for patients carrying BRAFmutant colorectal tumors (Fig. 6) .
DISCUSSION
Tumors carrying mutant KRAS or BRAF are associated with poor prognosis and therapeutic resistance. In addition, KRAS inhibitors are extremely toxic, and even though the recently developed BRAF and MEK inhibitors improve survival in melanoma patients, their use is limited because of the acquisition of drug resistance (4, 5, 13) . In this context, it is of paramount importance to identify new druggable targets downstream of the EGFR-KRAS-BRAF pathway, paying special attention to molecules that are currently used in the clinic for specific anticancer treatments or other therapeutic applications. Our results indicate that inhibitors of endosomal acidification (such as chloroquine, which is used for malaria prevention and treatment, and bafilomycin A1, an antibacterial, antifungal, and immunosuppressive agent) prevented phosphorylation of p45-IKKa in CRC cells without affecting NF-kB signaling. Our detection of multiple proteolytic IKKa fragments after proteinase K treatment compared with the detection only of p85 and p45 forms in the sucrose gradient experiments strongly suggested that full-length IKKa is likely associated with the outer membrane of the endosomes, although the exact localization of the different elements involved in endosomal p45-IKKa activation remains an open question. In any case, the fact that p45-IKKa inhibition by bafilomycin A1 specifically prevents the proliferation of BRAF-mutant cancer cells both in culture and in vivo is clinically relevant. Moreover, the inhibition of endosomal acidification potentiates the effect of conventional chemotherapy in an orthotopic xenograft model of human CRC. Our results suggest that activation of p45-IKKa by BRAF is likely to require the endosomal shuttling of specific elements of the p45-IKKa complex and the association of p45-IKKa with active TAK1. Consistently, inactivation of TAK1 rapidly abrogated phosphorylation of p45-IKKa, leading to a subsequent reduction in total p45-IKKa quantity. These results indicate a functional link between IKK activation and TAK1 in BRAF-mutated cancer cells, which could also be therapeutically exploited.
Importantly and unexpectedly, we found that KRAS-and BRAF-mutant CRC cells are essentially different and that only mutant KRAS was capable of inducing the NF-kB pathway. In contrast, BRAF activates an IKKadependent (NF-kB-independent) signature that includes the apoptosis regulators BIRC5 and BCL2L1, the migration related genes CD44, ECT2, or MCAM, and the cell cycle genes AURKA and CDC25A, as well as many other genes that regulate specific tumor features. Treating BRAF-mutant CRC cells with bafilomycin A1 reduced the expression of this IKKadependent signature in culture. Unexpectedly, we did not detect a significant reduction in IKKa-dependent transcription in tumors treated with bafilomycin A1. This result would suggest (i) that a subset of bafilomycin A1-resistant cells that failed to down-regulate p45-IKKa activity exists and that these cells contributed to the tumor mass in the treated animals, or (ii) that the drug was not homogeneously distributed throughout the tumor during the duration of the treatment, which permits the growth of the untreated, p45-IKKa-active cell population therein.
Thus, our results provide a mechanistic explanation for the anticancer and antimetastatic effects of p45-IKKa inhibition and suggest the potential to target specific IKKa functions independent of NF-kB, which is essential from a therapeutic point of view because NF-kB inhibitors exhibit toxicity. Here, we showed that endosomal acidification inhibitors exhibit this selective inhibition and can be used in combination therapies to prevent the growth and metastasis of tumors carrying active p45-IKKa without increasing the toxicity of standard treatments. Our current goal is to identify additional and more effective inhibitors of endosomal function with higher specificity toward p45-IKKa. Nevertheless, the fact that endosomal acidification inhibitors do not exclusively block p45-IKKa may also be advantageous for CRC treatment. For instance, they could help limit the activity of other pathways regulated by the endosomes, such as Notch and Wnt, which are indeed activated in several types of cancer and regulate cancer-initiating cells.
In summary, we have identified a new signaling cascade downstream of BRAF that involves the endosomal compartment and leads to p45-IKKa activation. Consistently, inhibition of endosomal activity provides a previously unexpected approach for treating BRAF-mutated cancers that warrants further studies in the clinics.
MATERIALS AND METHODS

Plasmids
The expression plasmids MT-IKKa and MT-p45-IKKa EE were constructed by inserting the PCR-amplified corresponding region, using a hemagglutinin (HA)-IKKa and HA-IKKa EE , respectively, as a template, into the mammalian expression vector pcS2-MT. MT-IKKa S400W and MT-IKKa3M were constructed by using the QuikChange Site-Directed Mutagenesis Kit from Stratagene and according to the manufacturer's instructions. Specific shRNAs against IKKa (x-2811c1 and x-2866s1c1) and TAK1 (x-2844s1c1 and x-601s1c1) were from Sigma-Aldrich. For the infection experiments, lentiviral expression vectors for wild-type BRAF and BRAF V600E were a gift from the laboratory of M. Encinas. The lentiviral plasmid for KRAS G12V was constructed by inserting the PCR-amplified corresponding region, using HA-KRAS G12V as a template, into the lentiviral vector MSCV-IRES-GFP. Viral particles were produced using standard techniques. Antibodies against a-tubulin and b-catenin (c2206) were from SigmaAldrich. The antibody against HA (12CA5) was purchased from Covance, and the antibody detecting the myc tag (MT antibody) was the 9E10 hybridoma. The antibody recognizing human p45-IKKa (clone 881H3; Millipore) has been described previously (34) . The BRAF inhibitor (AZ628) was from Selleckchem, the MEK inhibitor (UO126) was from Cell Signaling Technology, and the PI3K inhibitor (LY294002) and p38 inhibitor (SB203580) were from Calbiochem. Bafilomycin A1, chloroquine (diphosphate salt), and the TAK1 inhibitor (5Z-7-oxozeaenol) were from Sigma-Aldrich. All drugs were prepared as specified by the manufacturer and used at the concentrations indicated in the figures or figure legends.
Antibodies and inhibitors
Cell lines, cultures, and viral production HEK 293T, HCT116, SW480, LS174, HT-29, LIM1215, WiDr, NIH-3T3, MCF10A, and MEF were grown in Dulbecco's modified Eagle's medium plus 10% fetal bovine serum. Recombinant lentiviruses were produced by transient transfection of HEK 293T cells according to Tronolab's protocols (http://tronolab.epfl.ch/page58122.html). Twenty micrograms of the transfer vector, 15 mg of the packaging plasmid (psPAX2), and 6 mg of the envelope plasmid (pMD2.G) were used. After 3 days, the supernatant was ultracentrifuged, and the viral pellet was resuspended in 100 ml of phosphate-buffered saline (PBS). Twenty microliters of fresh viral suspension was used per infection.
Transformation assays
MEFs from IKKa wild-type or knockout animals were seeded in six-well plates at a density of 5 × 10 4 cells per well and then transduced with the indicated plasmids. Cells were maintained in culture by changing the medium every other day. At the indicated endpoints (when foci turned apparent), plates were washed with PBS, fixed with 4% paraformaldehyde, and stained with methylene blue. Two independent investigators determined the number of foci obtained in each condition.
Dose-response assays in CRC cells
Subconfluent CRC cell cultures were obtained by seeding 0.5 × 10 4 cells per well in 24-well plates. The day after, cells were treated with the different compounds (or vehicle) at the indicated concentrations. Seventytwo hours after starting the treatment, cells were washed with PBS, fixed with 4% paraformaldehyde, stained with crystal violet for 20 min at room temperature, and then washed with water until the excess dye was completely removed. Plates were then scanned and quantified using ImageJ software. Results were then represented as the number of cells relative to those of the vehicle-treated cultures from at least three independent experiments. Dose-response curves and the IC 50 were calculated using the nonlinear regression curve and the dose-response equation with Prism software, respectively.
In vivo assay for standard chemotherapy and endosomal acidification agents
For CRC cell line xenograft experiments, 2 × 10 4 DLD1 or WiDr cells were resuspended in Matrigel and injected subcutaneously in nude mice. When palpable intra-abdominal masses were detected, mice were randomized into the different treatment groups: (i) placebo, (ii) bafilomycin A1 (1 mg/kg), and (iii) irinotecan (30 mg/kg) + bafilomycin A1. In all experiments, irinotecan was diluted in saline, whereas bafilomycin A1 was diluted in dimethyl sulfoxide and administered by intraperitoneal injection at a final concentration of 10%. To minimize side effects in the combined treatment groups, irinotecan was administered intravenously at days 2, 7, 13, and 18 by tail-vein injection, and bafilomycin A1 was administered daily but always 1 hour after irinotecan administration (when applicable). Animals were sacrificed at day 21 after starting the treatment, and all visible tumors were measured and photographed. Animals were kept under pathogen-free conditions, and all experimental procedures were approved by the Ethical Committee at the Institute of Biomedical Research of Bellvitge.
Western blot analysis and immunoprecipitation assays
Cells were lysed 30 min at 4°C in 300 ml of PBS plus 0.5% Triton X-100, 1 mM EDTA, 100 mM NA-orthovanadate, 0.25 mM phenylmethylsulfonyl fluoride, and complete protease inhibitor cocktail (Roche). For immunoprecipitation, supernatants were precleared for 2 hours with 1% bovine serum albumin, 1 mg of IgGs, and 50 ml of protein A Sepharose beads. Precleared lysates were incubated overnight with 3 mg of the indicated antibodies. Antibody-protein complexes were captured with 30 ml of scintillation proximity assay beads for 2 hours. After being washed, precipitates were analyzed by Western blotting using standard SDS-polyacrylamide gel electrophoresis (SDS-PAGE) techniques. In brief, protein samples were boiled in Laemmli buffer, run in 9% polyacrylamide gels, and transferred onto polyvinylidene difluoride membranes. The membranes were incubated overnight at 4°C with the appropriate primary antibodies. After being washed, the membranes were incubated with specific secondary horseradish peroxidase-linked antibodies from Dako and visualized using the enhanced chemiluminescence reagent from Amersham.
Cell fractionation
Nuclei were isolated in 0.1% NP-40 in PBS for 5 min on ice, followed by centrifugation at 1900 rpm, and then lysed in 50 mM tris-HCl (pH 7.5), 150 mM NaCl, 1% NP-40, 5 mM EGTA, 5 mM EDTA, 20 mM NaF, and complete protease inhibitor cocktail (Roche). Supernatants were recovered as the cytoplasmic fraction. For cytoplasm/nuclear/chromatin separations, cells were lysed in 10 mM Hepes, 1.5 mM MgCl 2 , 10 mM KCl, and 0.05% NP-40 (pH 7.9) for 10 min on ice and centrifuged at 13,000 rpm. Supernatants were recovered as the cytoplasmic fraction, and the pellets were lysed in 5 mM Hepes, 1.5 mM MgCl 2 , 0.2 mM EDTA, 0.5 mM dithiothreitol, and 26% glycerol and sonicated for 5 min three times to recover the soluble nuclear fractions. The remaining pellet included the chromatin fraction. Lysates were run in SDS-PAGE and transferred onto Immobilon-P transfer membranes (Millipore) for Western blot analysis.
Statistical analysis
Categorical data were compared by Fisher's exact test. A nonparametric analysis of variance was used for the analysis of the ordinal expression of the phosphorylated IKK data by applying a rank transformation on the dependent variable. The analysis was performed using SAS version 9.1.3 software (SAS Institute Inc.), and the level of significance was established at 0.05 (two-sided).
Tissue microarray preparation and immunohistochemistry
Formalin-fixed, paraffin-embedded tissue blocks of colorectal tumors were retrieved from the archives of the Tumor Bank of the Hospital del Mar (MarBiobanc). Multiple areas of invasive carcinoma, adenomatous lesions from the same surgical sample, and normal adjacent mucosa were identified on corresponding hematoxylin and eosin-stained slides. The tissue blocks were transferred to a recipient "master" block using a tissue microarrayer. Each core was 0.6 mm wide and spaced 0.7 to 0.8 mm apart. Paraffin sections of 4 mm were hydrated and permeabilized, and antigen retrieval was achieved by incubating with 10 mM citrate buffer overnight at 80°C. Primary antibodies were incubated overnight and then developed with the DAB system from Dako.
Flow cytometric analysis and cell sorting
Apoptosis was determined using the annexin V binding kit (from Pharmingen) following the manufacturer's instructions. For cell cycle profile determination, cells were fixed in ethanol for 2 hours on ice and then stained with propidium iodide overnight at 4°C. Cells were analyzed by flow cytometry on a FACSCalibur or LSR II (Becton Dickinson). All data were analyzed with FlowJo software (Tree Star Inc).
Endosome protection assays
To identify proteins that reside in the endosomal compartment, cells were pelleted, resuspended in a buffer containing 100 mM potassium phosphate (pH 6.7), 5 mM MgCl 2 , 250 mM sucrose, and digitonin (6.5 mg/ml), and incubated for 5 min at room temperature followed by 30 min on ice. After treatment, the digitonin solution was removed by centrifugation for 5 min at 13,000 rpm, and the pellets were resuspended in the same buffer without digitonin. Then, samples were divided and processed in three different ways: maintained untreated (input control), incubated with proteinase K (1 mg/ml; Invitrogen) to eliminate all proteins that were excluded from the endosomal compartment, or incubated with proteinase K plus 0.1% Triton X-100 to solubilize the endosomes and hydrolyze all proteins (negative control). After incubation for 10 min at room temperature, samples were boiled in loading buffer to stop the reaction and were directly used for Western blot analysis.
Sucrose gradients
Purification of EE by sucrose gradients was performed as previously described (40) . In brief, cells were washed twice with PBS, collected in homogenization buffer [250 mM sucrose, 3 mM imidazole (pH 7.4)], centrifuged, and resuspended in homogenization buffer. Cells were then disrupted mechanically by using a 22-gauge needle. Nuclei were discarded by centrifugation at 1500g for 15 min at 4°C, and postnuclear supernatants (PNS) containing the endosomal fraction were adjusted to 40.2% sucrose (w/v) and loaded at the bottom of an SW40 ultracentrifugation tube (UltraClear, Beckman Coulter). Consecutively, 35% sucrose, 25% sucrose, and homogenization buffer were added on top of the PNS to create a gradient. After centrifugation at 35,000g for 90 min at 4°C in a swing-out Beckman SW40 rotor, 800-ml fractions were collected from top to bottom of the tubes followed by Western blot analysis.
Microarray assay
We compared the transcriptomes of WiDr and HT29 cells left untreated, treated for 3 hours with the BRAF inhibitor, or transduced with shRNA against IKKa (all experiments were done in triplicate) using a whole human genome oligonucleotide microarray from Agilent (G4112A). Microarray data were processed with the R Bioconductor statistical framework (http://R-project.org), and the Limma package was used to determine the most differentially expressed genes across conditions. Values represented for each probe are the SDs after mean-centering the values in each row.
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